SiBone (NASDAQ:SIBN) Shares Climb 8.7% on Better-Than-Expected Earnings

Key Points

• SiBone shares rose 8.7% after the company reported a third-quarter loss of $0.08 per share, beating the $0.13 consensus estimate, while revenue reached $55.7 million versus expectations of $55.31 million.
• Operational momentum improved, with U.S. procedure volume up about 20%, adjusted EBITDA increasing 32.4% to $3.0 million, and operating cash flow reaching $5.9 million. The company ended the quarter with $146.3 million in cash and reaffirmed 2026 revenue guidance of $231 million to $233 million.
• Analysts remain generally positive, with seven Buy ratings and one Sell rating and an average price target of $24.33. However, SiBone remains unprofitable and insiders have sold shares worth approximately $4.7 million over the past 90 days.

SiBone (NASDAQ:SIBN - Get Free Report)'s stock price was up 8.7% on Tuesday after the company announced better than expected quarterly earnings. The company traded as high as $22.26 and last traded at $21.9880. Approximately 136,756 shares were traded during trading, a decline of 78% from the average daily volume of 614,324 shares. The stock had previously closed at $20.22.

The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The business had revenue of $55.70 million for the quarter, compared to analyst estimates of $55.31 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%.

Key Stories Impacting SiBone

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Third-quarter results exceeded estimates. SiBone reported a loss of $0.08 per share, narrower than the $0.13 analyst consensus, while revenue increased 14.5% year over year to $55.7 million, slightly above expectations. The improved earnings performance may support the stock. Si-Bone Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: Growth and cash generation improved. U.S. procedure volume grew approximately 20%, the active U.S. physician base rose 16% to 1,770, adjusted EBITDA increased 32.4% to $3.0 million, and operating cash flow reached $5.9 million. SiBone ended the quarter with $146.3 million in cash. SiBone Third-Quarter Results
• Positive Sentiment: Product and reimbursement catalysts remain in place. FDA clearance for the iFuse Granite Onyx breakthrough device and new reimbursement rules that could increase hospital payments by up to approximately $50,000 for qualifying procedures may accelerate adoption.
• Neutral Sentiment: Full-year revenue guidance is essentially unchanged. SiBone forecast fiscal 2026 revenue of $231 million to $233 million, compared with the $232.2 million consensus estimate. The guidance is reassuring but does not represent a material forecast increase. The company remains unprofitable, posting a $3.6 million quarterly net loss.
• Negative Sentiment: Insiders sold shares. SVP Michael Pisetsky sold 29,665 shares for about $655,893, reducing his position by 15.28%, while Anshul Maheshwari sold 3,738 shares for $84,105. Both retained sizable holdings, but the transactions could create modest sentiment pressure. SiBone Insider Sales

Wall Street Analyst Weigh In

SIBN has been the topic of a number of research analyst reports. TD Cowen boosted their price target on SiBone from $18.00 to $20.00 and gave the company a "buy" rating in a report on Tuesday, August 4th. Citigroup reiterated a "market outperform" rating on shares of SiBone in a report on Tuesday. Needham & Company LLC cut their price objective on SiBone from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Tuesday. Weiss Ratings upgraded SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 20th. Finally, UBS Group boosted their target price on SiBone from $24.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, August 4th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $24.33.

Insider Activity at SiBone

In other news, insider Anshul Maheshwari sold 3,738 shares of the stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $22.50, for a total value of $84,105.00. Following the completion of the transaction, the insider owned 214,497 shares of the company's stock, valued at approximately $4,826,182.50. This represents a 1.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey Dunn sold 20,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $18.47, for a total value of $369,400.00. Following the completion of the transaction, the director directly owned 16,057 shares of the company's stock, valued at $296,572.79. This represents a 55.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 238,371 shares of company stock valued at $4,738,916. 4.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On SiBone

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC lifted its holdings in shares of SiBone by 51.8% during the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company's stock valued at $132,649,000 after purchasing an additional 2,774,795 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of SiBone by 41.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company's stock worth $7,816,000 after purchasing an additional 182,465 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of SiBone by 101.6% in the 1st quarter. Renaissance Technologies LLC now owns 472,619 shares of the company's stock worth $5,969,000 after purchasing an additional 238,219 shares in the last quarter. Squarepoint Ops LLC grew its stake in shares of SiBone by 40.3% in the 2nd quarter. Squarepoint Ops LLC now owns 118,128 shares of the company's stock worth $1,928,000 after buying an additional 33,947 shares during the last quarter. Finally, Granahan Investment Management LLC grew its stake in shares of SiBone by 97.6% in the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company's stock worth $21,965,000 after buying an additional 858,942 shares during the last quarter. 98.11% of the stock is owned by hedge funds and other institutional investors.

SiBone Trading Up 9.9%

The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15. The company has a market cap of $985.46 million, a P/E ratio of -65.17 and a beta of 0.66. The stock has a 50-day moving average of $19.42 and a two-hundred day moving average of $16.45.

SiBone Company Profile

SI-BONE, Inc NASDAQ: SIBN is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.